Abvc Biopharma (ABVC) FCF Margin (2010 - 2025)
Abvc Biopharma's (ABVC) quarterly FCF Margin came in at 121.2% in Q3 2025, down 13667.0% on a YoY basis from N/an in Q3 2024, and up 99.66% quarter-over-quarter from 35713.84% in Q4 2024.
Powered by 
Analysis
Abvc Biopharma (ABVC) FCF Margin (2010 - 2025) Analysis & Trends
Abvc Biopharma (ABVC) has reported FCF Margin for 13 consecutive years, with 121.2% the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, FCF Margin fell 13667.0% year-over-year to 121.2%; the trailing twelve-month figure through Sep 2025 stood at 237.73% (up 6386.0% YoY), and the FY2025 full-year result was 9397.08%, down 904206.0% from the prior year.
- FCF Margin advanced to 121.2% in Q3 2025 per ABVC's latest filing, from 35713.84% in the prior quarter.
- Across five years, FCF Margin topped out at 6680.12% in Q4 2021 and bottomed at 79320.83% in Q1 2024.
- Historically, FCF Margin has averaged 10126.07% across 5 years, with a median of 1225.63% in 2022.
- The widest YoY moves for FCF Margin: up 1454904 bps in 2024, down 7815329 bps in 2024.
- Over 5 years, FCF Margin stood at 6680.12% in 2021, then sank by 101 bps to 78.3% in 2022, then sank by 25294 bps to 19882.82% in 2023, then tumbled by 80 bps to 35713.84% in 2024, then surged by 100 bps to 121.2% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 121.2%, 35713.84%, and 15.47% for Q3 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -18,629.40% |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -121.20% |
| Dec 31, 2024 | -35,713.84% |
| Sep 30, 2024 | 15.47% |
| Jun 30, 2024 | -180.49% |
| Mar 31, 2024 | -79,320.83% |
| Dec 31, 2023 | -19,882.82% |
| Sep 30, 2023 | -5,915.08% |
| Jun 30, 2023 | -14,729.53% |
| Mar 31, 2023 | -1,167.54% |
| Dec 31, 2022 | -78.30% |
| Sep 30, 2022 | -1,225.63% |
| Jun 30, 2022 | -1,103.17% |
| Mar 31, 2022 | -12,032.26% |
| Dec 31, 2021 | 6,680.12% |
| Sep 30, 2021 | -2,238.43% |
| Jun 30, 2021 | -4,592.74% |
| Mar 31, 2021 | -536.98% |
| Dec 31, 2020 | -3,518.15% |
| Sep 30, 2020 | -284.55% |
| Jun 30, 2020 | -625.19% |